Lung Cancer

Rearrangement during transfection (RET) fusions can result in gain- or loss-of-function mutations and unchecked cellular proliferation. Although RET fusions are present in only a small percentage of cases of non–small-cell lung cancer, evidence shows they may be meaningful drug targets.
There are several oncogenic driver mutations that are actionable for treatment in cases of NSCLC. Evidence has shown that molecularly targeted approaches can result in positive outcomes for patients with NSCLC, underscoring the importance of research into biomarker testing and molecular profiling.
Four retrospective studies on treatment with immune checkpoint inhibitors in patients with NSCLC have shown only limited clinical benefit in patients with RET-rearranged lung cancer.
Ongoing trials of two recently approved RET inhibitors, pralsetinib and selpercatinib, are producing encouraging safety and efficacy data in patients with RET fusion–positive NSCLC.
Page 6 of 12
Results 51 - 60 of 112